Showing 1 - 6 results of 6 for search 'Gerrit K', query time: 0.02s
Refine Results
-
1
-
2
Reinventing the nucleic acid vaccine with self-amplifying RNA by Geall AJ, Otten GR, Hekele A, Bogers W, Oostermeijer H, Mooij P, Gerrit K, Verschoor E, Banerjee K, Cu Y, Beard CW, Brito LA, Ulmer JB, Mandl CW, Barnett SW
Published 2012-09-01Article -
3
CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells by Leonie Hartl, JanWillem Duitman, Hella L. Aberson, Kan Chen, Frederike Dijk, Joris J.T.H. Roelofs, Mark P.G. Dings, Gerrit K.J. Hooijer, Pratika Y. Hernanda, Qiunwei Pan, Olivier R. Busch, Marc G.H. Besselink, Ton Boerman, Maikel P. Peppelenbosch, Maarten F. Bijlsma, C. Arnold Spek
Published 2020-09-01
Article -
4
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric... by Sandor Schokker, Stephanie O. van der Woude, Jessy Joy van Kleef, Daan J. van Zoen, Martijn G. H. van Oijen, Banafsche Mearadji, Ludo F. M. Beenen, Charlotte I. Stroes, Cynthia Waasdorp, R. Aarti Jibodh, Aafke Creemers, Sybren L. Meijer, Gerrit K. J. Hooijer, Cornelis J. A. Punt, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven
Published 2019-06-01
Article -
5
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Respo... by Charlotte I. Stroes, Sandor Schokker, Remco J. Molenaar, Ron A. A. Mathôt, Maarten F. Bijlsma, Stephanie O. van der Woude, João P. Belo Pereira, Gerrit K. J. Hooijer, Rob H. A. Verhoeven, Annemieke Cats, Cecile Grootscholten, Johanna W. van Sandick, Geert-Jan Creemers, Grard A. P. Nieuwenhuijzen, Nadia Haj Mohammad, Jelle P. Ruurda, Sybren L. Meijer, Maarten C. C. M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W. M. van Laarhoven
Published 2021-02-01
Article -
6
Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study by Lenka N. C. Boyd, Lenka N. C. Boyd, Lenka N. C. Boyd, Lynn E. Nooijen, Lynn E. Nooijen, Lynn E. Nooijen, Mahsoem Ali, Mahsoem Ali, Mahsoem Ali, Jisce R. Puik, Jisce R. Puik, Jisce R. Puik, Jasmine Moustaquim, Stephanie M. Fraga Rodrigues, Stephanie M. Fraga Rodrigues, Stephanie M. Fraga Rodrigues, Robert Broos, Robert Broos, Robert Broos, Ali Belkouz, Laura L. Meijer, Tessa Y. S. Le Large, Tessa Y. S. Le Large, Tessa Y. S. Le Large, Joris I. Erdmann, Gerrit K. J. Hooijer, Michal Heger, Michal Heger, Michal Heger, Hanneke W. M. Van Laarhoven, Hanneke W. M. Van Laarhoven, Eva Roos, Geert Kazemier, Geert Kazemier, Elisa Giovannetti, Elisa Giovannetti, Elisa Giovannetti, Joanne Verheij, Heinz-Josef Klümpen
Published 2023-10-01
Article